Study of anti-glioma of SEC in vivo and in combination with radiotherapy for glioma
- VernacularTitle:SEC对胶质瘤的体内杀伤及其联合放射治疗的研究
- Author:
Fan WANG
;
Qiang HUANG
;
Liying ZHOU
- Publication Type:Journal Article
- Keywords:
Superantigen;
Glioma;
Severe combined immunodeficiency mice;
Combined modality therapy
- From:
Chinese Journal of Immunology
1985;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the anti-glioma effects of lymphocyte activated by SEC in vivo and probe into therapy effects of SEC combing with operation,radiotherapy and chemotherapy.Methods:Experiment animals were SCID mice.With establishing animal model of glioma xenografted and immunity chimeric model of HuPBL-SCID,we observed the growth curve,survive time.With having operation,radiotherapy and chemotherapy,30 patients suffering from glioma were divided into control group,handle group 1 and 2,and then results were analyzed with MRI.Results:Growth curve shows:A,C and B group produced different suppress against glioma and its suppress rate were 58.5%,46.2% and 36.3%.The first death occurred at the 17th day in control group mice and all mice deaded at the 40th day.Contrasting to this,the first death occurred at the 40th day and 50% mice still were alive in group A until the day that experiment has just finished(60 day).Clinical material showed:The rate of effect(CR and PR) in control group was 40%,while the rate of effects was 50% in handle group 1 and 62.5% in handle group 2.Conclusion:SEC has extramaly potent anti-tumor activity against glioma.SEC combined with operation,radiatherapy and chemotherapy can raise treatment effect in patients with glioma.
